Compare AEHL & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEHL | ADVB |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.4M |
| IPO Year | 2007 | 2025 |
| Metric | AEHL | ADVB |
|---|---|---|
| Price | $2.01 | $0.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.0M | 1.3M |
| Earning Date | 12-26-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $98,773,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.99 | N/A |
| 52 Week Low | $1.13 | $0.31 |
| 52 Week High | $11.53 | $4.10 |
| Indicator | AEHL | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 36.50 |
| Support Level | $2.88 | $0.31 |
| Resistance Level | $3.21 | $0.40 |
| Average True Range (ATR) | 0.39 | 0.04 |
| MACD | -0.13 | -0.00 |
| Stochastic Oscillator | 12.18 | 24.71 |
Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.